Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 7512
© 2007 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hanna, N. H. Articles by Einhorn, L. Search for Related Content PubMed Articles by Hanna, N. H. Articles by Einhorn, L.

Abstract

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023

Indiana University, Indianapolis, IN; Kansas City Cancer Centers, Overland Park, KS; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University, St. Louis, MO; Goshen Health System, Goshen, IN; Medical Consultants, Ball Memorial Hospital, Muncie, IN; Cancer Care Center, New Albany, IN; Ft. Wayne Oncology and Hematology, Ft. Wayne, IN

7512

Background: Concurrent chemoradiation is standard treatment for pts with inoperable stage III NSCLC. A previously reported single-arm, phase II study by SWOG (Gandara et al JCO 2003) suggested D following EP/XRT further improved survival. We report results from a randomized, prospective phase III trial comparing EP/XRT with or without consolidation D. Methods: Eligible pts had inoperable, stage IIIA/B NSCLC, PS 0–1, FEV-1 1 L, and < 5% wt loss. Pts (n=243) received P 50 mg/m² iv d 1,8,29,36 and E 50 mg/m² iv d1–5, 29–33 concurrently with chest XRT to 5940 cGy. Non-progressing pts were randomized to D 75 mg/m² iv every 21 d for 3 cycles vs observation (O). The primary endpoint was to compare OS (Kaplan-Meier analysis). Accrual of 259 pts to randomize180 was planned to demonstrate a difference in MST of 25 vs 15 mos (5% 2-sided alpha, 80% power). Based upon evidence of futility (predefined as p>0.7271), a DSMB recommended early termination after an analysis of the initial 203 pts. Results: Median f/u 25.6 mos. Pt characteristics (n=203): 34%/66% F:M; median age 63; 39.4%/60.6% IIIA/B. G3/4 toxicities during EP/XRT included 9.8% febrile neutropenia (FN), 17.2% esophagitis. 147 of 203 pts (72.4%) were randomized to D (n=73) or O (n=74). G3/4 toxicities during D included: 10.9% FN, 8.2% pneumonitis. 28.8% of pts were hospitalized during D (vs 8.1% in O arm) and 5.5% died due to D. PFS for D was 12.3 vs 12.9 mos for O (p=0.9412). The MST for all pts was 21.15 mos; MST for D was 21.6 mos (95% C.I. 17.7–35) vs 24.2 mos for O (95% C.I. 18.1–34.4) (p=0.9402). Conclusions: The MST with EP/XRT was higher than historical controls; however, consolidation D does not further improve survival, is associated with significant toxicity including an increased rate of hospitalization and premature death, and should no longer be used for pts with unresectable stage III NSCLC.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis

Abstract presentation from the 2007 ASCO Annual Meeting